Neurocrine Biosciences
Stock Forecast, Prediction & Price Target
Neurocrine Biosciences (NBIX) stock Price Target by analysts
$151.2
Potential upside: 13.84%
Neurocrine Biosciences price prediction
What is Neurocrine Biosciences stock analysts` prediction?
Neurocrine Biosciences stock forecast: Based on 4 Wall Street analysts` predicted price targets for Neurocrine Biosciences in the last 3 months, the avarage price target is $151.2, with a high forecast of $NaN. The average price target represents a 13.84% change from the last price of $132.81.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Neurocrine Biosciences stock Price Target by analysts
Full breakdown of analysts given Neurocrine Biosciences price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Evan David Seigerman BMO Capital | 0% 0/2 | 10 months ago | $121 -8.89% downside | $120.27 | StreetInsider | Previous targets (1) |
Jay Olson Oppenheimer | 0% 0/2 | 11 months ago | $192 44.56% upside | $116.57 | StreetInsider | Previous targets (1) |
Danielle Brill Raymond James | 50% 1/2 | 11 months ago | $155 16.70% upside | $111.62 | TheFly | Previous targets (1) |
Evan David Seigerman BMO Capital | 0% 0/2 | 12 months ago | $128 -3.62% downside | $122.29 | StreetInsider | Previous targets (1) |
Carter Gould Barclays | 50% 1/2 | 12 months ago | $160 20.47% upside | $120.17 | TheFly | Previous targets (1) |
David Amsellem Piper Sandler | 50% 1/2 | about 1 year ago | $159 19.71% upside | $128.43 | StreetInsider | Previous targets (1) |
Brian Abrahams RBC Capital | 0% 0/2 | about 1 year ago | $136 2.40% upside | $123.76 | TheFly | Previous targets (1) |
Jeffrey Hung Morgan Stanley | 0% 0/1 | about 1 year ago | $170 28.00% upside | $146.5 | TheFly | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/2 | over 1 year ago | $141 6.16% upside | $133.69 | StreetInsider | Previous targets (1) |
Ashwani Verma UBS | 0% 0/1 | over 1 year ago | $193 45.32% upside | $139.4 | StreetInsider | Previous targets (0) |
Cory Kasimov Evercore ISI | 0% 0/1 | over 1 year ago | $175 31.76% upside | $136.15 | TheFly | Previous targets (0) |
Andrew Fein H.C. Wainwright | 66.67% 2/3 | over 1 year ago | $160 20.47% upside | $143.03 | StreetInsider | Previous targets (2) |
Sumant Kulkarni Canaccord Genuity | 50% 1/2 | over 1 year ago | $164 23.48% upside | $143.03 | TheFly | Previous targets (1) |
Mohit Bansal Wells Fargo | 0% 0/1 | over 1 year ago | $170 28.00% upside | $139.35 | StreetInsider | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | over 1 year ago | $200 50.59% upside | $137.74 | StreetInsider | Previous targets (1) |
Unknown Morgan Stanley | N/A | over 2 years ago | $130 -2.11% downside | $108 | Benzinga | N/A |
Marc Goodman SVB Securities | 100% 1/1 | almost 3 years ago | $115 -13.41% downside | $119.36 | TipRanks Contributor | Previous targets (0) |
Andrew Fein H.C. Wainwright | 66.67% 2/3 | almost 3 years ago | $140 5.41% upside | $119.36 | TipRanks Contributor | Previous targets (2) |
Brian Skorney Robert W. Baird | 50% 1/2 | almost 3 years ago | $150 12.94% upside | $119.36 | TheFly | Previous targets (1) |
David Amsellem Piper Sandler | 50% 1/2 | almost 3 years ago | $103 -22.44% downside | $119.36 | TheFly | Previous targets (1) |
Andrew Fein H.C. Wainwright | 66.67% 2/3 | over 3 years ago | $140 5.41% upside | $86.52 | TipRanks Contributor | Previous targets (2) |
Marc Goodman Leerink Partners | 100% 1/1 | over 3 years ago | $100 -24.70% downside | $85.53 | TipRanks Contributor | Previous targets (0) |
Paul Matteis Stifel Nicolaus | 100% 1/1 | over 3 years ago | $136 2.40% upside | $85.53 | StreetInsider | Previous targets (0) |
Danielle Brill Raymond James | 50% 1/2 | over 3 years ago | $125 -5.88% downside | $85.53 | StreetInsider | Previous targets (1) |
Brian Skorney Robert W. Baird | 50% 1/2 | over 3 years ago | $117 -11.90% downside | $85.53 | TipRanks Contributor | Previous targets (1) |
Tazeen Ahmad Bank of America Securities | 100% 1/1 | over 3 years ago | $127 -4.37% downside | $75.51 | StreetInsider | Previous targets (0) |
Carter Gould Barclays | 50% 1/2 | over 3 years ago | $100 -24.70% downside | $72.8 | TheFly | Previous targets (1) |
Neena Bitritto-Garg Citigroup | 100% 1/1 | over 3 years ago | $129 -2.86% downside | $84.26 | TheFly | Previous targets (0) |
Charles Duncan Cantor Fitzgerald | 100% 1/1 | almost 4 years ago | $123 -7.38% downside | $95.58 | TheFly | Previous targets (0) |
Joshua Schimmer Evercore ISI | 100% 1/1 | almost 4 years ago | $130 -2.11% downside | $95.58 | TipRanks Contributor | Previous targets (0) |
Sumant Kulkarni Canaccord Genuity | 50% 1/2 | about 4 years ago | $108 -18.68% downside | $89.57 | StreetInsider | Previous targets (1) |
Laura Chico Wedbush | 100% 1/1 | about 4 years ago | $112 -15.66% downside | $93.2 | StreetInsider | Previous targets (0) |
Neurocrine Biosciences Financial Estimates
Neurocrine Biosciences Revenue Estimates
Neurocrine Biosciences EBITDA Estimates
Neurocrine Biosciences Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.13B N/A | $1.48B 31.33% | $1.88B 26.76% | Avg: $2.55B Low: $2.43B High: $2.77B avg. 35.20% | Avg: $2.97B Low: $2.82B High: $3.21B avg. 16.51% | Avg: $3.34B Low: $3.18B High: $3.62B avg. 12.59% | Avg: $3.80B Low: $3.61B High: $4.11B avg. 13.61% |
Net Income
% change YoY
| $89.6M N/A | $154.5M 72.43% | $249.7M 61.61% | Avg: $674.78M Low: $482.78M High: $860.52M avg. 170.23% | Avg: $916.49M Low: $639.33M High: $1.10B avg. 35.81% | Avg: $1.06B Low: $1.00B High: $1.18B avg. 16.72% | Avg: $1.31B Low: $1.23B High: $1.45B avg. 22.75% |
EBITDA
% change YoY
| $207.8M N/A | $249M 19.82% | $358M 43.77% | Avg: $597.91M Low: $570.42M High: $650.60M avg. 67.01% | Avg: $696.66M Low: $662.81M High: $753.66M avg. 16.51% | Avg: $784.38M Low: $746.27M High: $848.56M avg. 12.59% | Avg: $891.21M Low: $847.90M High: $964.13M avg. 13.61% |
EPS
% change YoY
| $0.95 N/A | $1.61 69.47% | $2.56 59.00% | Avg: $6.34 Low: $4.78 High: $8.52 avg. 147.67% | Avg: $8.72 Low: $6.33 High: $10.93 avg. 37.57% | Avg: $10.59 Low: $9.92 High: $11.72 avg. 21.42% | Avg: $13 Low: $12.18 High: $14.38 avg. 22.75% |
Operating Expenses
% change YoY
| $911.4M N/A | $1.21B 33.47% | $1.59B 31.23% | Avg: $1.20B Low: $1.14B High: $1.30B avg. -24.75% | Avg: $1.39B Low: $1.33B High: $1.51B avg. 16.51% | Avg: $1.57B Low: $1.49B High: $1.70B avg. 12.59% | Avg: $1.79B Low: $1.70B High: $1.93B avg. 13.61% |
FAQ
What is Neurocrine Biosciences stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 61.38% in 2025-2028.
We have gathered data from 15 analysts. Their low estimate is 482.78M, average is 674.78M and high is 860.52M.
What is Neurocrine Biosciences stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 19.48% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $2.43B, average is $2.55B and high is $2.77B.
What is Neurocrine Biosciences stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 57.35% in 2025-2028.
We have gathered data from 15 analysts. Their low earnings per share estimate is $4.78, average is $6.34 and high is $8.52.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Neurocrine Biosciences stock. The most successful analyst is Evan David Seigerman.